Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)

BACKGROUND: High‐dose pharmaceutical‐grade biotin (MD1003) has positive effects on disability in progressive multiple sclerosis (PMS), but its mechanism of action remains unclear. The objective of our study was to quantify the effect of MD1003 in patients with PMS, using clinical response, plasma ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Collongues, Nicolas, Kuhle, Jens, Tsagkas, Charidimos, Lamy, Julien, Meyer, Nicolas, Barro, Christian, Parmar, Katrin, Amann, Michael, Wuerfel, Jens, Kappos, Ludwig, Moreau, Thibault, de Seze, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882156/
https://www.ncbi.nlm.nih.gov/pubmed/33314801
http://dx.doi.org/10.1002/brb3.1998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882156/
https://www.ncbi.nlm.nih.gov/pubmed/33314801
http://dx.doi.org/10.1002/brb3.1998

Ejemplares similares